Scarica l'app Stockscreener
15.60
13.72%
-2.48
Dopo l'orario di chiusura:
15.50
-0.10
-0.64%
Precedente Chiudi:
$18.08
Aprire:
$16
Volume 24 ore:
6.73M
Relative Volume:
6.17
Capitalizzazione di mercato:
$1.11B
Reddito:
$114.04M
Utile/perdita netta:
$-330.15M
Rapporto P/E:
-3.2981
EPS:
-4.73
Flusso di cassa netto:
$-274.85M
1 W Prestazione:
-5.97%
1M Prestazione:
+4.70%
6M Prestazione:
+72.95%
1 anno Prestazione:
+124.46%
Intervallo 1D:
$15.15
$16.06
Intervallo di 1 settimana:
$15.15
$18.09
Portata 52W:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Confronta PHAT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
15.60 | 1.29B | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Iniziato | Raymond James | Strong Buy |
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
How Phathom Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Update & Safe Investment Capital Preservation Plans - ulpravda.ru
Latham & Watkins Advises Phathom Pharmaceuticals on US$130 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
Phathom Pharmaceuticals Announces $130 Million Public Offering - TipRanks
Form 424B5 Phathom Pharmaceuticals, - StreetInsider
Phathom Pharmaceuticals shares fall 13.1% after co announces $130 mln equity raise - MarketScreener
Can Phathom Pharmaceuticals Inc. stock hit analyst price targetsTrade Performance Summary & Technical Entry and Exit Tips - ulpravda.ru
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Phathom Pharmaceuticals (PHAT) Benefits from Joint Book Running Managers - GuruFocus
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Phathom Pharmaceuticals tumbles on $130 mln equity raise - TradingView — Track All Markets
Phathom Pharmaceuticals prices $130 million public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Phathom Pharmaceuticals (PHAT) Launches $130M Public Offering - GuruFocus
Phathom Pharmaceuticals (PHAT) Prices Public Offering, Stock Dips - GuruFocus
Phathom (PHAT) Stock Pre-Market (-12%): Prices $130M Stock Offering at Discount - Trefis
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Phathom Pharmaceuticals, Inc.Common Stock (NQ: PHAT - FinancialContent
Phathom Pharmaceuticals drops after announcing planned equity raise - TradingView — Track All Markets
PHAT Forecasts Profitable Operations by 2026 - GuruFocus
Phathom Pharmaceuticals stock falls on planned public offering - Investing.com
Phathom Pharmaceuticals stock falls on planned public offering By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals files for mixed shelf offering size not disclosedSEC filing - MarketScreener
Phathom Pharma plans public offering after reporting preliminary 2025 results - MSN
Phathom Pharmaceuticals Reports Q4 Preliminary Revenue of $$57 Million to $58 Million - MarketScreener
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Phathom Pharmaceuticals: Speculative Biotech Name Rides A Fresh Wave Of Volatility - AD HOC NEWS
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Phathom Pharmaceuticals grants RSUs and options to CEO Steven Basta | PHAT SEC FilingForm 4 - Stock Titan
(PHAT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Movement Recap: What makes Phathom Pharmaceuticals Inc stock attractive to growth funds2025 Big Picture & Real-Time Buy Signal Alerts - moha.gov.vn
Simplify Asset Management Inc. Reduces Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Hits New 52-Week HighHere's What Happened - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Is Expected To Breakeven In The Near Future - Yahoo Finance
Phathom Pharmaceuticals stock hits 52-week high at $17.87 By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals stock hits 52-week high at $17.87 - Investing.com India
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Is Phathom Pharmaceuticals Inc. stock oversold or undervaluedTrade Entry Summary & Community Consensus Picks - Улправда
Bull Run: Why Phathom Pharmaceuticals Inc. stock is favored by pension funds2025 Winners & Losers & Weekly Stock Performance Updates - Улправда
Is Phathom Pharmaceuticals Inc. stock cheap at current valuationWeekly Profit Report & Daily Profit Maximizing Tips - DonanımHaber
Will Phathom Pharmaceuticals Inc. stock benefit from AI adoptionBear Alert & Verified Momentum Watchlists - Улправда
Is Phathom Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Update Summary & Expert Curated Trade Setup Alerts - Улправда
Market Moves: Is Phathom Pharmaceuticals Inc. stock oversold or undervalued2025 Winners & Losers & Consistent Income Trade Ideas - Улправда
US Market Wrap: Is Phathom Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 1-Year HighWhat's Next? - MarketBeat
Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Earnings Haven't Escaped The Attention Of Investors - 富途牛牛
Earnings Recap: Can Phathom Pharmaceuticals Inc stock weather global recessionPortfolio Gains Report & Real-Time Stock Entry Alerts - moha.gov.vn
Phathom Pharmaceuticals Inc Stock Analysis and ForecastEarnings Miss Alerts & Affordable Portfolio Tips - earlytimes.in
Raymond James Financial Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):